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1.3.1 Principles of description and methods of abbreviation
General findings are often described as findings. In such
cases, the ‘‘f’’ representing general findings may be omit-
ted, and a description such as ‘‘MtLt, 10 cm, Type 2, T2,
N0, M0, Stage II’’ is acceptable. When clinical findings
need to be distinguished from pathological findings,
descriptions such as ‘‘Although surgery was performed
based on a preoperative finding of cT2,cN0, the patho-
logical finding was pT3,pN1’’ are acceptable.
2.1 Description of primary tumor
2.1.1. The number and size of the lesions needs to be
described; if multiple peripheral tumors are present, the
location, size, tumor type, and depth of invasion should be
described for each lesion. In cases with multiple lesions,
the major lesion is the deepest lesion (or the lesion with the
largest dimension if the depth of tumor invasion is equal).
In cases where evaluation using X-ray or endoscopy is
only possible in one direction, the largest dimension
measured should be described as the clinical finding.
2.1.2. Tumor location
[Diagnostic criteria for cancer located at the esopha-
gogastric junction]
The esophagogastric junction (EGJ) should be defined
systematically in accordance with the criteria listed below.
It is important that a diagnosis be made before the initiation
of treatment. Endoscopic findings should be prioritized
over findings obtained using other diagnostic modalities.
Cancer at the EGJ means that the tumor center is located
between 2 cm proximal to and distal from the EGJ. When
the tumor size or tumor invasion makes it difficult to define
the EGJ, the location of the EGJ should be comprehen-
sively identified based on general findings. In such
instances, the tumor location should be described with an
acknowledgement that the diagnosis was not based on strict
diagnostic criteria for EGJ cancer.
1. Endoscopic findings
The EGJ is defined as the lower margin of palisading small
vessels (Fig. 2-1a–c).
If the palisading small vessels cannot be clearly identified,
the oral margin of the longitudinal folds of the greater
curvature of the stomach can be defined as the EGJ (Fig. 2-
1d).
j Commentary: Esophageal sphincters are located at both
the proximal and distal ends of the esophagus and are
referred to as the upper esophageal sphincter (UES) and the
lower esophageal sphincter (LES), respectively. The pro-
pria mucosa layer of these two loci contains palisading
small vessels that penetrate the muscularis mucosa layer
after branching from submucosal vessels. Since the
sphincter muscles are considered to be a feature of the
esophagus, the esophagus is defined as the tract between
the upper margin of the UES and the lower margin of the
LES. Because the lower margin of the LES is defined as the
EGJ, the level of the EGJ can be defined as the level of the
lower margin of the lower palisading vessels. With this
interpretation in mind, the majority of Japanese experts
define the EGJ endoscopically as the lower margin of the
lower palisading vessels. The endoscopic observation of
palisading small vessels should be performed under a
condition in which the lower esophagus is adequately
stretched after suctioning the air from inside the stomach
and the examinee has inhaled deeply.
Fig. 2-1 a The lower margin of the palisading small vessels and the
oral margin of the longitudinal folds of the greater curvature of the
stomach are both clearly visible and coincident at the same level. In
such cases, this site of coincidence is defined as the EGJ and is nearly
identical to the SCJ. b The lower margin of the palisading small
vessels and the oral margin of the longitudinal folds of the greater
curvature of the stomach are both clearly visible and coincident at the
same level. In such cases, this site of coincidence is defined as the
EGJ (black arrows). The gap between the SCJ and the EGJ is
diagnosed as Barrett esophagus. c The palisading small vessels are
visible, but the longitudinal folds are unclear. The lower margin of the
palisading small vessels is defined as the EGJ (black arrows). The gap
between the SCJ and the EGJ is diagnosed as Barrett esophagus.
d The longitudinal folds are visible, but the lower margin of the
palisading vessels is unclear. The upper oral margin of the
longitudinal fold is defined as the EGJ (black arrows). The gap
between the SCJ and the EGJ is diagnosed as Barrett esophagus
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The palisading small vessels may be difficult to distin-
guish in endoscopic examinations of cases with gastroe-
sophageal reflux disease or long segment Barrett esophagus
(LSBE). Also, constant esophageal stretching cannot be
attained by a deep inhalation if the patient has been sedated.
The majority of Western experts have long used the crite-
rion that the EGJ be defined as the upper end of the longi-
tudinal folds of the stomach. The EGJ is defined as the
upper end of the longitudinal folds of the stomach in the
Prague C&M Classification, developed by the International
Working Group for the Classification of Oesophagitis
(IWGCO) in 2006. Endoscopic observation of the upper end
of the longitudinal folds should be performed with optimal
decompression of the stomach through suction; however,
‘‘optimal decompression’’ has not been strictly defined. The
oral margin of the longitudinal folds of the stomach cannot
be reliably defined if the amount of air inside the stomach
varies. Thus, the diagnostic concordance rate is not very
high for the detection of short segment Barrett esophagus
(SSBE) extending for lengths smaller than 1 cm. Moreover,
the gastric folds tend to be smaller in the presence of
atrophic gastritis, which is more common in Japan, and the
upper end of the longitudinal folds cannot be reliably
observed if the amount of gas inside the stomach varies.
With these points in mind, the upper end of the longitudinal
folds can be difficult to define in some cases.
In making a diagnosis, the EGJ should be defined with a
comprehensive interpretation of both the palisading small
vessels and the longitudinal folds. In Japan, LSBE is less
common and atrophic gastritis is more common. Therefore,
in the Japanese Classification of Esophageal Cancer, the
lower margin of the palisading vessels is primarily used to
define the EGJ. The upper end of the longitudinal folds is
used as a secondary criterion in cases where the palisading
vessels are difficult to distinguish.
2. X-ray: Upper gastrointestinal series
• The EGJ is defined as the narrowest locus of the lower
esophagus (Fig. 2-2).
• In cases with a sliding hiatal hernia, the EGJ should be
identified as the oral margin of the longitudinal folds
(Fig. 2-3).
• In the presence of Barrett esophagus, the SCJ is located
on the oral side of the EGJ, and Barrett mucosa appears
as mucosa containing reticular structures in a double-
contrast study (Fig. 2-4). The EGJ is identified as the
oral margin of the longitudinal folds.
j Commentary: In a barium contrast series, the esophagus
can be divided into two segments of tubular and vestibule
(or saccular) esophagus with a junction called the
tubulovestibular junction, where the lumen of the esopha-
gus gradually narrows. The Angle of His designates the
angle formed by the esophagus and the fornix of the
stomach. In healthy subjects, the Angle of His is acute, and
the EGJ is identical to the narrowest part of the lower
esophageal lumen. A muscular fiber lies between the left
side of the esophagus and the entry of the stomach,
resulting in the acuteness of the Angle of His. This fiber is
located inside the propria muscle of the stomach and is
called the ‘‘sling fiber’’. In healthy subjects, the level of the
EGJ is nearly identical to the level of the SCJ.
Fig. 2-2 Barium contrast image of a normal EGJ
Fig. 2-3 Barium contrast image of the EGJ in a subject with a hiatal
hernia
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j Commentary: In cases with a hiatal hernia, a circular
‘‘neck’’ of the esophageal lumen is observed close to the
hiatus or at the lower level of the pleural cavity during a
barium contrast study, and this neck is referred to as a
mucosal ring (B ring) or ‘‘Z-line’’. Although this neck is
referred to as a ‘‘ring’’, the ring is not formed by a circular
fiber of the muscular propria. Instead, the ‘‘ring’’ is pre-
sumably formed by the sling fiber and is prominent on the
left side, or the fornix side, of the esophagus. In cases with
a hiatal hernia, the EGJ is usually imaged as the oral
margin of the longitudinal folds of the stomach.
j Commentary: The ‘‘circular neck’’ of the esophagus
accompanying a hiatal hernia is often obscured in the
presence of Barrett mucosa. Therefore, the EGJ is usually
defined as ‘‘the oral margin of the longitudinal folds of the
stomach’’ in subjects with Barrett mucosa.
3. Pathological study
Macroscopic definition: The EGJ should be defined
macroscopically as the point at which the luminal caliber
changes in the area where the tubular esophagus is con-
nected to the vestibule lumen of the stomach.
Microscopic definition: For a mucosal layer with intact
structures, the EGJ should be defined as follows:
1. Non-Barrett esophagus: The EGJ is defined as the
squamocolumnar junction.
2. Barrett esophagus: Histological structures such as
proper esophageal glands and their ducts, a double-layer
muscularis mucosa, or palisading small vessels should be
included in the microscopic definition of the EGJ.
For a non-intactmucosal layer, theEGJ should be definedbased
on the macroscopic findings of the surgical specimen, and the
EGJ should be presumed based on the presence of histological
structures associated with the esophagus or stomach.
j Commentary: To define the EGJ, the surgical specimen
must be fully extended and optimally fixed. The histolog-
ical structures must be examined using a full section of the
whole specimen. If the palisading small vessels are visible
in a fresh specimen, the anal margin of the vessels should
be marked before the histological inspection. The EGJ is
defined as ‘‘the borderline between the muscular structures
of the esophagus and the stomach’’; however, histological
discrimination of the muscular structures of each area is
difficult. The EGJ is also often histologically unclear.
Therefore, the histological definition of the EGJ depends
on the macroscopic findings or the histological features of
the mucosal or submucosal layer.
The definition of the histological EGJ should be given
individually for non-Barrett esophagus and Barrett esoph-
agus cases.
 Non-Barrett esophagus
The SCJ is identical to the level of the lumen where
the esophagus connects to the stomach and the
macroscopic luminal caliber changes; this location
is approximately identical to the EGJ. The SCJ can be
visualized using Lugol staining, appearing as a linear
or slightly curved borderline between squamous and
columnar epithelium. In cases with a hiatal hernia, the
luminal caliber change tends to be obscured, but the
EGJ can often be defined after a closer inspection.
` Barrett esophagus
The SCJ is not identical to the EGJ.
(a) Non-circular Barrett esophagus
The line of the SCJ adjacent to the non-
Barrett epithelium is identical to the EGJ.
(b) Circular Barrett esophagus
The EGJ can be defined as the most anal
level of the lumen where any of the follow-
ing histological features are observed:
Presence of proper esophageal glands or esopha-
geal gland tubules beneath the columnar epithelium
Presence of squamous islands in the columnar
epithelium
Presence of a double-layer muscularis mucosae
beneath the columnar epithelium
Palisading vessels
Fig. 2-4 Barium contrast image of the EGJ in a subject with Barrett
mucosa
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The level of the luminal caliber change is included in the
definition of the EGJ.
[Cancer at the EGJ]
Since the pattern of lymph node metastasis for EGJ cancer
differs from that of carcinomas of the lower esophagus or
the upper stomach, special attention should be paid to the
surgical procedure. Consequently, EGJ cancer is dealt with
separately in the Japanese Classification. Previously,
Nishi’s classification was used for the definition of EGJ
cancer. According to this classification, EGJ cancer
includes lesions with a tumor center located between 2 cm
proximal to and distal from the EGJ, irrespective of his-
tology (Fig. 2-5). Accordingly, cancer of the abdominal
esophagus is included in EGJ cancer.
In Western countries, Siewert’s classification is com-
monly used. According to Siewert’s classification, cancer
at the EGJ is defined as adenocarcinoma with a tumor
center located within 1 cm distal from and 2 cm proximal
to the EGJ (Fig. 2-6). EGJ cancer corresponds to Siewert
Type II-True cardia cancer.
Adenocarcinoma in Barrett esophagus cannot be
excluded from a diagnosis of EGJ cancer located in the
abdominal esophagus.
Note 1: In cancers located at the EGJ, the oral and anal
portions of the EGJ are described as ‘‘E’’ and ‘‘G’’,
respectively. As shown in Fig. 2-3, the terms ‘‘E, EG, E=G,
GE, and G’’ can be used depending on the tumor location.
Note 2: In cases with adenocarcinoma in Barrett
esophagus, the disease should be described.
Note 3: Siewert’s classification Types I, II and III
(Fig. 2-6) should also be described for adenocarcinoma
located in the lower esophagus or at the EGJ (Fig. 2-7).
[References]
(1) Nishi M, Kajisa T, Akune T, et al. Cardia cancer—proposal of cancer
in the esophagogastric junction (in Japanese). Geka Shinryo (Surgical
Diagnosis and Treatment) 1973; 15: 1328–1338.
(2) Siewert JR, Stein HJ. Carcinoma of the cardia: carcinoma of the
gastroesophageal junction—classification, pathology and extent of resec-
tion. Dis Esophagus 1996; 9: 173–182.
(3) Japanese Gastric Cancer Association. Japanese Classification of Gastric
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2.1.3. Macroscopic tumor type
2.1.3.2. Macroscopic classification (Figs. 2-8, 2-9, 2-10)
Type 0 Superficial type: Tumor invasion is limited to the
submucosa.
Type 1 Protruding type: localized protruding lesion.
The definitely protruding lesion which commonly
has an erosive surface. However, the lesion is
occasionally covered by intact squamous
epithelium continuing from surroundings.
Type 2 Ulcerative and localized type: The ulcerative
lesion has a well-demarcated surrounding ridge.
Type 3 Ulcerative and infiltrative type: The ulcerative
lesion has an ill-demarcated surrounding ridge
circumferentially or semi-circumferentially.
Type 4 Diffusely infiltrative type: Lesion with wide
intra-mural invasion, and generally without con-
spicuous ulcer or protrusion. Even if the lesion
has ulcerative and/or protruding components, it is
defined as type 4.
Fig. 2-6 Definition and description of adenocarcinoma at the esoph-
agogastric junction according to Siewert’s classification
Fig. 2-7 Subclassification and methods of description of cancer at
the esophagogastric junction
Fig. 2-5 Definition and description of esophagogastric junction
according to Nishi’s classification
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Fig. 2-9 Roentgenological findings: advanced type
Fig. 2-10 Endoscopic findings: advanced type. a1 Type 1, protruding
type (pT2): a tall lesion with a broad base. a2 Type 1, protruding type
(pT2): a tall lesion with a narrow base. b Type 2, ulcerative and
localized type (pT3): a deep ulcerative lesion surrounded by a well-
demarcated ridge. c Type 3, ulcerative and infiltrative type (pT3): a
deep ulcerative lesion surrounded by an ill-demarcated ridge. d Type
4, diffusely infiltrative type (pT3): ill-defined thickening and hard-
ening of the esophageal wall accompanied by luminal stenosis is
observed. There is no remarkable ulcer formation
Fig. 2-8 a Type 1: a pedunculated and tall polypoid lesion. This was
judged to be advanced cancer based on its size, mobility (or cut cross
section). b Type 1: this protruding type lesion with a clearly demarcated
border has lobules or a papillary appearance on its surface. cType 1:most
of the surface of the protrusion is covered by non-cancerous epithelium.
This was judged to be advanced cancer based on its size and immobility.
d Type 2: this lesion is a deep ulcer with a well-demarcated surrounding
ridge. Macroscopic findings: advanced type (Types 1–5). e Type 3: this
lesion is a deepulcer surroundedbyapoorlydemarcated ridge.The lesion
extended circumferentially causing luminal stenosis. f Type 4: this
diffusely invasive lesionwith no clear marginmakes the esophageal wall
thick and hard, and causes luminal stenosis. No distinct ulcer can be seen.
g Type 4: the thickening of the esophageal wall and the edematous
changes of themucosa suggest diffuse intramural extension of the lesion,
but there is no finding of hardening or stenosis, and no finding of ulcer
formation. h Combined type: this cancer showed mixed morphology of
advanced Type 1 and Type 2 (0-IIc Type extension can be seen in part).
i Type 5a: the macroscopic appearance is extremely complex with Type
1, and Type 2 and others, and it is difficult to categorize. j Type 5b: this
macroscopic tumor (Type 5b) cannot be categorized because of
preoperative chemoradiotherapy. iType 5a: themacroscopic appearance
is extremely complex with Type 1, and Type 2 and others, and it is
difficult to categorize. j Type 5b: This macroscopic tumor (Type 5b)
cannot be categorized because of preoperative chemoradiotherapy
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Type 5 Unclassifiable type: The lesion with a compli-
cated macroscopic appearance which is unclas-
sifiable to any of macroscopic tumor types 0–4.
5a The unclassifiable lesion without previous
treatment.
5b The lesion unclassifiable because of a
changed appearance with previous
treatment.
The lesion after treatment(s) should be classified into
macroscopic tumor types 0–4 if possible. The lesion with
previous treatment(s) should be distinguished with the sign
of treatment.
2.1.3.3. Subclassification of superficial type (Figs. 2-11, 2-
12, 2-13)
Type 0-I Superficial and protruding type: definitely
protruding lesion diagnosed as superficial
cancer, based on findings of size, height and
a relatively narrow basis.
Type 0-Ip Pedunculated: lesion with a peduncle or semi-
peduncle, and generally the height is more
conspicuous than the horizontal spread of the
base.
Type 0-Is Sessile (broad based): lesion without a pedun-
cle, and generally the horizontal spread of the
base is more conspicuous than the height.
Types of 0-Ipl and 0-Isep in the 9th edition of
the Japanese Classification are included in this
type.
Type 0-II Superficial and flat type: the lesion without
definite protrusion or depression.
Type 0-IIa Slightly elevated type: lesion with a slight
elevation (up to about 1 mm in height).
Type 0-IIb Flat type: the lesion without macroscopic
elevation or depression. This cancerous
lesion can occasionally be recognized
only by iodine staining.
Type 0-IIc Superficial and depressed type: lesion
with a slight depression, commonly
accompanied with mucosal reddening.
The degree of depression is equivalent
to erosion.
Type 0-III Superficial and depressed type: lesion show-
ing more distinct depression than the 0-IIc
type, and bottom of the depression appears to
extend beyond the muscularis mucosae
(Fig. 2-14).
2.1.4 Depth of tumor invasion (T)
Depth sub-typing for superficial cancer
In surgically resected tissue specimens, the mucosal
layer T1a is divided into three layers (T1a-EP, T1a-LPM,
and T1a-MM), and the submucosal layer T1b is also
divided into 3 layers (T1b-SM1, T1b-SM2, and T1b-SM3)
(Fig. 1-3).
In endoscopically resected specimens, lesions located
within 200 lm of the muscularis mucosae are identified as
T1b-SM1, and lesions invading beyond this range are
identified as T1b-SM2.
2.2 Metastatic lesions from esophageal cancer
2.2.1 Lymph node metastasis
In Japan, regional lymph nodes are classified as ‘‘com-
partment 1 to 3’’ according to tumor location, while distant
lymph nodes are categorized as ‘‘compartment 4’’. Based
on this lymph node grading classification, the degree of
lymph node metastasis (N classification) is defined as N0–
N4. On the other hand, the UICC (International Union
Against Cancer) TNM classification defines lymph nodes
located in the defined area as ‘‘regional lymph nodes’’
regardless of the tumor location. The degree of lymph node
metastasis is described as N0–N3 based on number of
lymph node metastases. Metastasis to lymph nodes other
than regional lymph nodes is categorized as M1.
2.2.1.1 Naming, number, range and boundary of regional
lymph node
(1) Cervical lymph nodes (Fig. 2-15)
No.100 Superficial lymph nodes of the neck
The cervical lymph nodes except for the deep cervical
nodes according to the General Rules for Clinical
Studies on Head and Neck Cancer
No.100spf Superficial cervical lymph nodes: Lymph
nodes located along the external jugular veins and
anterior jugular veins beneath the superficial cervical
fascia.
No.100sm Submandibular lymph nodes: Lymph nodes
located around the submandibular glands and parotid
glands, and anterior to the mylohyoid muscle.
No.100tr Cervical pretracheal lymph nodes: Lymph
nodes located in the pretracheal fatty tissue,
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extending from the hyoid bone superiorly, to the left
brachiocephalic vein inferiorly, including the prethy-
roidal lymph nodes and the prelaryngeal lymph
nodes.
No.100ac Accessory nerve lymph nodes: Lymph nodes
located along the accessory nerve(s), and anterior to the
trapezius muscle.
No.101 Cervical paraesophageal lymph nodes
Lymph nodes located around the cervical esophagus,
including lymph nodes located along the recurrent
laryngeal nerve and the cervical paratracheal lymph
nodes. The lateral boundary is the medial border of the
carotid sheath. A distinction between left and right must
be included.
No.102 Deep cervical lymph nodes
Lymph nodes located around the internal jugular vein
and the common carotid artery.
No.102up Upper deep cervical lymph nodes: Lymph
nodes located from the caudal border of the digastric
muscle superior to the carotid artery bifurcation.
No.102mid Middle deep cervical lymph nodes: Lymph
nodes located from the carotid artery bifurcation supe-
riorly to the lower border of the cricoid cartilage
inferiorly.
No.103 Peripharyngeal lymph nodes
Lymph node located medial to the carotid sheath,
extending from the caudal border of the digastric muscle
bFig. 2-11 Macroscopic findings: superficial type (0 type). a Type
0-Ip (superficial and protruding type, pedunculated): The tumor is
well demarcated and has a narrow base. b Type 0-Ip (superficial and
protruding type, pedunculated): The well-demarcated, protruding
tumor has an irregular and nodular surface. c Type 0-Is (superficial
and protruding type, sessile): the surface of this ill-demarcated tumor
is mostly covered by the normal epithelium. d Type 0-IIa (slightly
elevated type): the tumor is only slightly elevated from the mucosa.
Its color is generally white. e Type 0-IIb (flat type): there are only
minute irregularities and no macroscopic abnormal features. f Type
0-IIb (flat type) (iodine-stained view of e) the superficial tumor can
now be seen unstained by iodine. g Type IIc (slightly depressed type):
the superficial depressed lesion has no clear margin and a finely
granular surface. h (iodine-stained view of g): the superficial tumor is
unstained by iodine. i Type 0-IIc (slightly depressed type): the
superficial depressed lesion has an irregular margin. j Type 0-III
(superficial and depressed type): the deeply depressed lesion with a
slightly elevated margin suggests invasion beyond the muscularis
mucosae. k Type 0-IIc?’’0-IIa’’ (superficial spreading type): the
widespread slightly depressed red lesion (0-IIc) has a slightly elevated
lesion (0-IIa) in its center, suggesting invasion into the submucosal
layer. The lesion, more than 5 cm in length, is defined as the
superficial spreading type. l Type 0-IIc?’’0-IIa’’ (superficial spread-
ing type) (iodine-stained view of k): the reddish depressed lesion is
not stained with iodine solution. m Type 0-IIc ? ‘‘0-Ip’’: the well-
demarcated protruding tumor with a narrow base (0-Ip) has a slightly
depressed lesion (0-IIc) in the surrounding area. This macroscopic
appearance is characterized as carcinosarcoma
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superiorly to the lower border of the cricoid cartilage
inferiorly. Postpharyngeal and parapharyngeal lymph
nodes are included.
No.104 Supraclavicular lymph nodes
Lymph nodes located in the supraclavicular fossa,
extending from the lower border of the cricoid
cartilage superiorly, to the clavicle inferiorly, includ-
ing the lower internal deep cervical lymph nodes.
The medial boundary is the medial border of the
carotid sheath. A distinction between left and right
must be included.
(2) Thoracic lymph nodes (Figs. 2-16, 2-17, 2-18, 2-19, 2-
20, 2-21, 2-22, 2-23)
No.105 Upper thoracic paraesophageal lymph nodes
Lymph nodes located around the upper thoracic esoph-
agus posterior to the right vagus nerve on the right side.
Lymph nodes located along the azygos vein arch and the
right bronchial artery are included. The superior bound-
ary is drawn from the cephalic border of the subclavian
arteries to the suprasternal notch.
No.106 Thoracic paratracheal lymph nodes
Lymph nodes located along the anterior and lateral wall
of the thoracic trachea.
No.106rec Recurrent nerve lymph nodes: Lymph nodes
located along the recurrent laryngeal nerves in the
mediastinum. The superior boundary is drawn from the
cephalic border of the subclavian arteries to the
suprasternal notch, and the inferior boundary is the
caudal border of the recurrent laryngeal nerve curving
upward on both sides.
No.106recL Left recurrent nerve lymph nodes
Lymph nodes located along the left recurrent laryngeal
nerve
No.106recR Right recurrent nerve lymph nodes
Lymph nodes located along the right recurrent laryngeal
nerve
No.106pre Pretracheal lymph nodes
Lymph nodes located in front of the anterior wall of the
thoracic trachea, and anterior to the right vagus nerve.
No.106tb Tracheobronchial lymph nodes
Lymph nodes located in the tracheobronchial angle.
No.106tbL Left tracheobronchial lymph nodes: The
superior border is the inferior wall of the aortic
arch, and the lymph nodes are located in the area
surrounded by the medial wall of the aortic arch.
No.106tbR Right tracheobronchial lymph nodes:
The superior border is the inferior wall of the
azygos vein.
No.107 Subcarinal lymph nodes
Lymph nodes located caudal to the carina of the
trachea. The lateral boundaries are the extended
line of both lateral margins of the trachea.
No.108 Middle thoracic paraesophageal lymph nodes
Lymph nodes located around the middle thoracic
esophagus.
No.109 Main bronchus lymph nodes
Lymph nodes located in the caudal area of the main
bronchus. The internal boundary is the border of
subcarinal lymph nodes, and the external boundary
is the lung.
No.110 Lower thoracic paraesophageal lymph nodes
Lymph nodes located around the lower thoracic
esophagus.
No.111 Supradiaphragmatic lymph nodes
Lymph nodes located in the area surrounded by the
diaphragm, pericardium, and esophagus.
Fig. 2-12 Radiological findings: superficial type
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No.112 Posteriormediastinal lymphnodes:Lymphnodes
located in the area surrounded by the descending aorta,
inferior pulmonary vein and pericardium. These lymph
nodes are divided into the following subgroups.
No.112aoA Anterior thoracic paraaortic lymph
nodes: Among lymph nodes located around the
descending aorta, lymph nodes existing on the same
side of the esophagus, including lymph nodes along
the thoracic duct.
No.112aoP Posterior thoracic paraaortic lymph
nodes: Among lymph nodes located around the
descending aorta, lymph nodes existing on the
opposite side of the esophagus.
No.112pul pulmonary ligament lymph nodes:
Lymph nodes located in the pulmonary ligament(s),
including lymph nodes adjacent to the pericardium
bFig. 2-13 Endoscopic findings: superficial type. a Type 0-Ip, super-
ficial and protruding type, pedunculated (cT1b-SM2-3): a well-
demarcated protruding and pedunculated tumor shows an irregular
and nodular surface. b Type 0-Is, superficial and protruding type,
sessile (pT1b-SM2): a well-demarcated protruding and sessile tumor.
c Type 0-Is, superficial and protruding type, sessile (pT1b-SM2): 
Conventional endoscopy: an ill-demarcated protruding tumor covered
by normal esophageal mucosa suggests a tumor mass in the
submucosa. ` Iodine staining: the mucosa covering the tumor is
stained brown, and an unstained area at the top suggests exposed
tumor tissue. d Type 0-IIa, slightly elevated type (pT1a-MM): a
plaque-like, slightly elevated white tumor. Tumor invasion of the
white area remained within the lamina propria, while a tiny protrusion
at the distal margin of the tumor had invaded the muscularis mucosae.
e Type 0-IIa, slightly elevated type (pT1a-EP): a slightly elevated
tumor with well-demarcated reddening (the height of a type 0-IIa
lesion is less than 1 mm). f Type 0-IIb flat type (pT1a-EP): 
Conventional endoscopy: a conventional observation could not detect
the lesion. ` Narrow band imaging shows a brownish area. ´ Iodine
staining: a completely flat lesion was identified as a well-demarcated,
unstained area using iodine staining. g Type 0-IIc, slightly depressed
type (pT1a-LPM).  Conventional endoscopy: an irregularly shaped
mucosal reddening with a slight depression is visible. ` Narrow band
imaging: the lesion is also visible as a brownish area. ´ Iodine
staining: a well-demarcated, unstained area is visible using iodine
staining. h Type 0-IIc, slightly depressed type (pT1b-SM1): 
Conventional endoscopy: an area of mucosal reddening with a slight
depression and marginal elevation is visible. ` Narrow band imaging:
a brownish area suggesting a hypervascular lesion is visible. i Type
0-III, superficial and excavated type (cT1b-SM2-3).  Conventional
endoscopy, ` narrow band imaging (cT1b-SM2-3): a distinctly
depressed lesion with a surrounding elevated area is visible using
conventional observations, suggesting an ulcer reaching the muscu-
laris mucosa. j Combined type 0-IIc ? ‘‘0-Is’’ (pT1b-SM2): 
Conventional endoscopy: a distinct elevation with a wide base is
visible. A slightly depressed lesion was also noted close to the distal
margin of the lesion. ` Narrow band imaging: a lesion with a well-
demarcated margin is visible. k Combined type 0-Is ? 0-IIc (pT1b-
SM2):  Conventional endoscopy: a distinctly protruding lesion with
a wide base and irregular, nodular changes is visible. Reddening of
the esophageal mucosa close to the lesion with an ill-defined margin
was suspected. ` Iodine staining: The margins of the mucosal
changes were identified as well-demarcated, unstained areas
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and the inferior pulmonary vein. A distinction
between left and right must be included.
No.113 Ligamentum arteriosum lymph nodes (Botallo
lymph nodes)
Lymph nodes located on the left side of the arterial
ligament.
No.114 Anterior mediastinal lymph nodes
Lymph nodes located anterior to the superior vena
cava, including lymph nodes of the brachiocephalic
venous angle and lymph nodes around the thymus
gland.
Fig. 2-13 continued
Fig. 2-14 Diagnostic criteria for depth of invasion. a T1a-EP (Tis):
carcinoma in situ. b T1a-LPM: tumor has invaded the lamina propria
mucosae. c T1a-MM: tumor has invaded the muscularis mucosae.
d T1b-SM1: tumor invasion is limited to the upper third of the
submucosal layer. The vertical depth of invasion is 180 lm from the
lower edge of the muscularis mucosae. The lesion was diagnosed as
pT1b-SM1 in the endoscopically resected specimen
Fig. 2-15 Cervical lymph nodes. Tr tracheal, Thy thyroid, IJ internal
jugular vein, CC common carotid artery, E esophagus
48 Esophagus (2017) 14:37–65
123
(3) Abdominal lymph nodes (Fig. 2-24)
The names, numbers and extent of abdominal lymph nodes
are defined by the ‘‘Japanese Classification of Gastric
Cancer’’.
[References]
(1) Japan Society for Head and Neck Cancer. General Rules for Clinical
Studies on Head and Neck Cancer (in Japanese). 5th ed. Kanehara
Shuppan, Toyko, 2012
(2) Japanese Gastric Cancer Association. Japanese Classification of Gas-
tric Carcinoma (in Japanese). 14th ed. Kanehara Shuppan, Tokyo, 2010
2.2.1.2 Lymph node groups
In cervical esophageal cancer, lymph nodes No.105 and
No.106rec are defined as those present in an area that could
be dissected through a cervical incision.
2.4 Multiple primary cancers
Synchronous tumors: diagnosed within a period of 1 year.
Metachronous tumors: diagnosed after an interval of 1 year
or more.
Cases with both synchronous and metachronous tumors are
defined as synchronous/metachronous tumors.
3.4.3 Lymph node dissection
3.4.3.1 Types of lymph node dissection
Cervical lymph node dissection indicates bilateral dissec-
tion including No.101 and No.104.
3.7 Curativity
Curativity for transhiatal esophagectomy
The extent of lymph node dissection is defined as D0 after
a transhiatal esophagectomy.
In cases with cN0 and cM0, curability is determined based
on the pathological depth of tumor invasion.
pT1a (EP or LPM), D0 and pR0: fCurA.
pT1a-MM, pT1b, pT2, pT3, D0 and pR0: fCurB.
4.2.1. Histological classification
4.2.1.1. Benign epithelial neoplasms
1. Squamous cell papilloma
Squamous cell papilloma shows papillary growth of
squamous epithelium with no atypism. This tumor occa-
sionally has clear cytoplasm with vacuoles, suggesting
Fig. 2-16 Superior mediastinal lymph nodes
Fig. 2-17 Upper mediastinal lymph nodes in the level above the
aortic arch
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papilloma virus infection. It is important that this lesion
should be differentiated from verrucous carcinoma in
biopsy specimens.
2. Adenoma
Adenoma is a rare neoplasm in squamous-lined esophagus.
A few reports have described esophageal adenoma arising
from a proper esophageal gland or its duct.
Note: Several cases of a peculiar type of benign tumor in
Barrett esophagus have been reported. However, there is no
consensus regarding the diagnostic criteria or the methods
of description for adenoma in Barrett esophagus.
4.2.1.2. Intraepithelial neoplasia
1. Squamous intraepithelial neoplasia (Fig. 2-25)
Intraepithelial neoplasia is defined as a lesion showing
structural and cytological abnormalities that can be
regarded as indicating a neoplasm; however, it does not
include carcinoma in situ.
Note: There are two types of intraepithelial neoplasia;
intraepithelial neoplasia of the squamous epithelium and
intraepithelial neoplasia of the columnar epithelium in
Barrett esophagus. The details of the intraepithelial
neoplasia of the squamous epithelium are explained
below. Intraepithelial neoplasia of columnar epithelium
is described in the section on esophageal adenoma.
Explanation
1. Intraepithelial neoplasia is a neoplastic lesion that
exhibits structural and cytological abnormalities but does
not include carcinoma. Previously, this lesion was formally
known as dysplasia, but it has been referred to as intraep-
ithelial neoplasia since the publication of the WHO clas-
sification (2000) and the 10th edition of the Japanese
classification (2008). Intraepithelial neoplasia has been
classified into two groups: low grade and high grade. In the
10th edition, high-grade intraepithelial neoplasia included
lesions that could be diagnosed as squamous cell
Fig. 2-18 Upper mediastinal lymph nodes at the level of the aortic
arch
Fig. 2-19 Upper mediastinal lymph nodes in the level below the
aortic arch
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carcinoma in situ in Japan. Since the 11th edition includes
the diagnosis of squamous cell carcinoma in situ, the pre-
vious two-tier subclassification of low grade and high grade
has been abolished.
2. Of note, a peculiar type of squamous cell carcinoma
in situ mimicking a ‘‘low-grade intraepithelial neoplasia’’
according to the diagnostic criteria of the 10th edition has
been reported. Although such tumor cells differentiate
towards the epithelial surface, the cell density (cellularity)
is increased and the cell arrangement (polarity) is irregular
in the basal and parabasal layers of the epithelium. Cellu-
larity in the epithelial surface is also increased, compared
with non-neoplastic lesions. The nuclei of the tumor cells
are uniform. However, they are occasionally large. Iodine-
unstained lesions more than 10 mm in diameter mimicking
low-grade intraepithelial neoplasia should be suspected as
being a carcinoma in situ.
Note: Differential diagnoses of intraepithelial neoplasia
include lesions that exhibit reactive atypism as a result of
inflammation and regeneration. For instance, regenera-
tive squamous epithelium in cases with reflux esophagi-
tis sometimes exhibits atypical basal or parabasal cells,
but these lesions should not be diagnosed as intraep-
ithelial neoplasia. Lesions in which the differentiation of
neoplasm from reactive changes is difficult should be
diagnosed as ‘‘atypical epithelium’’ or ‘‘atypical epithe-
lium, indefinite for neoplasia’’.
4.2.1.3. Malignant epithelial neoplasms
Histological subtyping should be done based on the pre-
dominant histological features of the tumor.
1. Squamous cell carcinoma (Figs. 2-26, 2-27, 2-28, 2-29,
2-30)
Squamous cell carcinoma in situ is equivalent to squa-
mous cell carcinoma showing pT1a-EP. Invasive squamous
cell carcinoma forms solid nests of tumor cells that dif-
ferentiate toward stratified squamous epithelium.
Fig. 2-20 Mediastinal lymph nodes in the level below the carina
Fig. 2-21 Lower mediastinal lymph nodes in the level of the inferior
pulmonary vein
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Keratinization, stratification, and intercellular bridges are
frequently observed. A few tubules and a small amount of
epithelial mucus may exist in the tumor; these features
should be noted, if present.
Note: Squamous cell carcinoma in situ can be diagnosed
based on structural and cytological atypia. Structural
atypia includes cellular density (cellularity), cell differ-
entiation, loss of polarity at the basal layer, etc.
Cytological atypia includes variations in nuclear size
and shape, hyperchromasia, loss of polarity, prominent
nucleoli, an increased nuclear/cytoplasmic ratio, and
mitoses. There is no need to describe the degree of
differentiation in squamous cell carcinoma in situ.
Invasive squamous cell carcinoma is subclassified into
three groups based on squamous differentiation: well
differentiated, moderately differentiated, and poorly
differentiated. Verrucous carcinoma, a type of very
well differentiated squamous cell carcinoma with papil-
lary growth, is a rare tumor in the esophagus (Fig. 2-31).
Poorly differentiated squamous cell carcinoma can be
composed of spindle-shaped cells and may resemble
Fig. 2-22 Lower mediastinal lymph nodes in the level of the right
atrium
Fig. 2-23 Lower mediastinal lymph nodes in the level above the
hiatus
Fig. 2-24 Abdominal lymph nodes
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sarcoma; such lesions should be classified as spindle cell
carcinoma or a spindle cell variant of SCC.
2. Basaloid (-squamous) carcinoma (Fig. 2-32)
Basaloid (-squamous) carcinoma consists of relatively
small cells that resemble basal cells and that grow in a solid
or trabecular pattern, occasionally forming irregular ade-
noid or small cystic structures. This entity is also charac-
terized by hyalinization both within and outside tumor
nests, and the hyaline material is the same as that in the
basement membrane. Duct-like structures may be
Fig. 2-25 Squamous intraepithelial neoplasia. a Low magnification
of squamous intraepithelial neoplasia. The lesion is visible as an
iodine-unstained area measuring 3 mm in size. Histologically, the
lesion is well demarcated. b High magnification. The tumor shows
mild nuclear atypia with low cellular density and a regular
arrangement of the basal layer. c Histology of biopsy specimen.
The lesion is visible as an iodine-stained tan area measuring 5 mm in
size. Histopathologically, a mildly thickened epithelium exhibits
atypical cell proliferation in the lower two-thirds of the epithelium,
but nuclear atypia is mild and the basal layer has a regular
arrangement
Fig. 2-26 Squamous cell carcinoma (pT1a-EP). a Low-power view
of squamous cell carcinoma. The border between the carcinoma and
non-neoplastic epithelium is clear. b Histology of the border between
the squamous cell carcinoma and the non-neoplastic squamous
epithelium. The cancer tissue exhibits a high cellular density with a
loss of the basal layer. c Histology of the central portion of cancer
tissue. The cancer cells have proliferated throughout the entire
epithelial layer, but have not invaded the lamina propria mucosae
Fig. 2-27 Basal layer-type squamous cell carcinoma (pT1a-EP).
a Cancer cells are present within the lower half of the epithelium, whereas
squamous epithelial cellswithminimal atypia are present in the upper half.
b High-power view of the above figure. The basal cells have disappeared
and the lower half of the epithelium has been replaced by cancer cells with
nuclear atypia and a higher cellular density. Squamous epithelial cells in
the upper half are small in size and have a lower cellular density
Fig. 2-28 Squamous cell carcinoma with invasion into the lamina
propria mucosae (pT1a-LPM). a Squamous cell carcinoma shows
mild thickening and irregular downward growth. b Droplet infiltration
is observed in the lamina propria mucosae. c Expansive growth of
squamous cell carcinoma
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observed. Squamous cell carcinoma frequently coexists
with basaloid squamous carcinoma in the intraepithelial
area and is occasionally present in invasive areas.
3. Carcinosarcoma (Fig. 2-33)
Carcinosarcoma is composed of both carcinomatous and
sarcoma-like components. These tumors include carcinoma
consisting of spindles or polymorphous tumor cells with a
mesenchymal character, and they can contain neoplastic
bone and cartilage components. When a tumor is accom-
panied by various differentiations such as chondrosarcoma
and osteosarcoma, each component should be noted in the
Fig. 2-29 Squamous cell carcinoma with invasion into the muscu-
laris mucosae (pT1a-MM). a Cancer cells have reached the upper end
of the muscularis mucosae and have partly invaded the muscularis
mucosae. Both situations are classified as pT1a-MM. b Cancer cells
have invaded the muscularis mucosae, but not beyond
Fig. 2-30 Squamous cell carcinoma. a Well differentiated squa-
mous cell carcinoma: cancer pearls with marked keratinization are
observed. b Moderately differentiated squamous cell carcinoma:
sheet-like arrangement of tumor cells with slight keratinization is
observed. c Poorly differentiated squamous cell carcinoma: kera-
tinization is not observed, although tumor cells show sheet-like
arrangement
Fig. 2-31 Verrucous squamous carcinoma. a Gross features of
verrucous carcinoma. The tumor involves the cervical esophagus
and lower pharynx. The tumor has a granular surface. b Low-power
view of verrucous carcinoma. Note that papillary growth is prominent
and the basal layer is generally flat. c Verrucous carcinoma with
invasion into the lamina propria mucosae. d High-power view of
verrucous carcinoma. The tumor has a high cellular density with an
irregular arrangement at the basal site. However, squamous differen-
tiation is apparent towards the surface
Fig. 2-32 Basaloid squamous carcinoma. a Basaloid squamous
carcinoma is often covered by non-neoplastic stratified squamous
epithelium and grows downwards. The tumor forms a solid nest with
occasional cyst formation and necrosis. b Tumor cells similar to basal
cells form solid nests in various sizes under stratified squamous
epithelium. c Tumor cells show a solid and trabecular arrangement.
Eosinophilic basement membrane-like material deposits are present
around and within the tumor nest. d Basaloid squamous carcinoma
sometimes contains duct-like differentiation
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pathological diagnosis. This tumor often shows polypoid
growth with a stalk, characterized by the presence of
squamous cell carcinoma in situ surrounding the stalk.
Tumors showing prominent proliferation of reactive mes-
enchymal cells should also be included in carcinosarcoma.
4. Adenocarcinoma (Fig. 2-34)
Esophageal adenocarcinoma should be classified in the
same manner as gastric carcinoma. Most tumors arise from
Barrett esophagus. Esophageal adenocarcinoma rarely
arises from ectopic gastric mucosa.
Note: In adenocarcinoma located predominantly in the
lower esophagus, if the tumor is considered to be gastric
cancer with esophageal invasion, its possible origin
should be noted in the pathological diagnosis.
5. Adenosquamous carcinoma (Fig. 2-35)
Adenosquamous carcinoma has both components of ade-
nocarcinoma and squamous cell carcinoma, each compo-
nent of which can be easily recognized. When either of the
two components is limited to a very small area (less than
20%), the tumor should be classified as a major component,
with an additive note regarding the minor component (e.g.
squamous cell carcinoma with an adenocarcinoma
component).
6. Mucoepidermoid carcinoma (Fig. 2-36)
Mucus-containing cells (adenocarcinoma cells) are pre-
sent within nests of squamous cell carcinoma. There are
usually no distinct tubular structures. The mucus-con-
taining cells may be goblet or signet ring cell type. Mucus
is occasionally discharged into the stroma and intercel-
lular spaces.
7. Adenoid cystic carcinoma (Fig. 2-37)
Adenoid cystic carcinoma is a very rare tumor with the
same histological appearance as a salivary gland. Small
cells with scanty cytoplasm form cribriform structures,
solid nests or trabecular structures. Mucus within small
Fig. 2-33 Carcinosarcoma.aAlarge tumor protrudes into the esophageal
lumen. The tumor has not invaded deeply, in comparison with its size.
b The polypoid tumor mainly consists of spindle cells, and its surface is
covered by squamous cell carcinoma. c A large part of the tumor
(sarcomatous component) is occupied by spindle-shaped tumor cells with
scattered small foci of squamous cell carcinoma. d Tumor cells with
prominent polymorphous nuclei are present in the sarcomatous compo-
nent, which is similar to pleomorphic undifferentiated sarcoma (formerly
diagnosed as malignant fibrous histiocytoma [MFH])
Fig. 2-34 Adenocarcinoma in non-Barrett esophagus. a Well differ-
entiated adenocarcinoma is observed proximal to the squamocolum-
nar junction. bWell differentiated adenocarcinoma is present beneath
the squamous epithelium. Barrett mucosa is not observed, so that the
origin of the tumor is unknown
Fig. 2-35 Adenosquamous carcinoma. Adenosquamous carcinoma
consists of squamous cell carcinoma and adenocarcinoma. Invasive
squamous cell carcinoma is present on the oral side of the tumor, and
adenocarcinoma is mainly present on the anal side
Fig. 2-36 Mucoepidermoid carcinoma. a Signet ring cell carcinoma
is observed within squamous cell carcinoma. b Mucus in signet ring
cell carcinoma is stained blue by Alcian-blue staining. Serial section
of a
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cystic spaces inside and outside the tumor nests stains light
blue with Alcian blue-PAS. There is no epithelial mucus
production in the cribriform areas, unlike in adenocarci-
noma with a cribriform pattern. A pattern of small duct-like
structures is occasionally seen in which ducts consist of
tumor cells aligned in a double layer containing epithelial
mucus. This tumor should be carefully distinguished from
basaloid squamous carcinoma.
8. Neuroendocrine cell tumor (Fig. 2-38)
Neuroendocrine cell tumors include both neuroendocrine
tumors (formerly known as carcinoid tumors) and neuroen-
docrine carcinoma (formerly known as endocrine cell car-
cinoma). Neuroendocrine tumors of the esophagus are very
rare and have the same histological appearance as neuroen-
docrine tumors located in other organs. Neuroendocrine
carcinoma forms nests of tumor cells in various sizes and
occasionally shows a trabecular or ribbon-like growth pat-
tern or rosette formation. This tumor can be classified into
two types: small cell type and non-small cell type (mixed
type of small and large cells). Definitive diagnosis needs
immunohistochemical positivity of endocrine markers such
as chromogranin A, synaptophysin, and CD56 (N-CAM).
Note: Tumors exhibiting neuroendocrine differentiation
were formerly diagnosed as undifferentiated carcinoma.
Neuroendocrine carcinoma can be distinguished from
undifferentiated carcinoma by the presence of neuroen-
docrine differentiation.
9. Undifferentiated carcinoma
This tumor shows medullary growth pattern consisting of
small and large tumor cells, lacking particular cell and
structural differentiation. Various histopathological meth-
ods fail to reveal any particular cell differentiation.
10. Others
This category includes malignant epithelial tumors that
cannot be classified in any of the above groups.
4.2.1.4. Non-epithelial tumors
1. Smooth muscle tumor (Fig. 2-39)
Histologically this tumor shows an interlacing pattern of
spindle-shaped tumor cells having elongated spindle nuclei
with tapered ends and having cytoplasm with eosinophilic
filaments. The epithelioid type shows nest-like growth
pattern composed of round-shaped tumor cells with eosi-
nophilic or clear cytoplasm. These tumors are often found
as a small nodule in the muscularis propria of the lower
esophagus or in the muscularis mucosae or the muscularis
propria of the mid-esophagus. This tumor shows positive
immunohistochemical reactions for a-smooth muscle actin
and desmin and a negative reaction for KIT (CD117).
Differentiation between benign and malignant tumor is
based on the cellularity, nuclear pleomorphism, and mitosis.
Fig. 2-37 Adenoid cystic carcinoma. a A tumor with duct-like
structures and a cribriform pattern has invaded downwards. b The
histology of esophageal adenoid cystic carcinoma is almost the same
as that with a salivary gland origin. Nuclear atypia is more prominent
in the esophageal tumor than in the salivary gland tumor
Fig. 2-38 Neuroendocrine carcinoma, small cell type. a Small round
cells with scant cytoplasm proliferate densely. b Tumor cells show an
irregular arrangement with trabecular or ribbon-like patterns. c Im-
munohistochemically, the tumor cells are positive for chromogranin
A, indicating differentiation to neuroendocrine cells
Fig. 2-39 Leiomyoma. a Spindle cells with eosinophilic cytoplasm
scantily grow in the fascicular pattern. b Immunohistochemically, the
tumor cells are positive for a-smooth muscle actin. c Tumor cells are
also positive for desmin
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Leiomyoma has no nuclear pleomorphism or mitotic fig-
ures and shows low cellularity, whereas leiomyosarcoma has
abundant mitotic figures and shows high cellularity.
2. Gastrointestinal stromal tumor (GIST) (Fig. 2-40)
This tumor shows histologic findings similar to a smooth
muscle tumor. It is occasionally difficult to differentiate
GIST from smooth muscle tumor without immunohisto-
chemical staining. GIST is defined as a mesenchymal tumor
that immunohistochemically exhibits KIT (CD117) and/or
DOG1 positivity. CD34 is positive in about 80% of GISTs.
Note: Risk assessment follows the Guidelines for the
Diagnosis and Treatment of GIST.
3. Granular cell tumor (Fig. 2-41)
Granular cell tumors, which are composed of large round
cells with eosinophilic granules in abundant cytoplasm, form
solid nests of various sizes and grow predominantly in the
lamina propria mucosae or submucosa. Stratified squamous
epithelium commonly covers these tumors, and they occa-
sionally exhibit pseudoepitheliomatous hyperplasia.
4.2.1.5. Lymphoid tumors
There have been a few case reports of B cell lymphoma of
the esophagus. The latest version of the WHO classification
is used for esophageal malignant lymphoma.
4.2.1.6. Other malignant tumors
1. Malignant melanoma (Fig. 2-42)
In order to make a diagnosis of primary malignant mela-
noma, histological identification of junctional activity that
tumor cells producing melanin granules proliferate in the
basal layer of the epithelium is needed.
2. Others
Choriocarcinoma has been reported in the esophagus.
4.2.2. Depth of tumor invasion (pT)
If the layers of the esophagus are destroyed by preoperative
treatment, the depth of tumor invasion should be described
based on the deepest layer where the primary tumor is con-
sidered to have been present before preoperative treatment.
4.2.9. Pathological criteria for the effects of radiation and/
or chemotherapy
Some of the findings regarded as therapeutic effect due to
radiation and chemotherapy are described below (Figs. 2-
43, 2-44, 2-45, 2-46).
Fig. 2-40 Gastrointestinal stromal tumor (GIST). a Spindle cells
densely proliferate with fascicular arrangement. b Mitotic figures are
shown among tumor cells with plump nuclei. c Immunohistochemi-
cally, the tumor cells are positive for KIT (CD117). d The Ki-67
(MIB-1) labeling index was 30%, indicating a high-risk tumor
Fig. 2-41 Granular cell tumor. a The tumor has grown mainly within
the lamina propria mucosae and is covered by stratified squamous
epithelium. b Large and round tumor cells exhibit abundant granular
and eosinophilic cytoplasm
Fig. 2-42 Malignant melanoma. a Short spindle-shaped or round
tumor cells with abundant melanin granules have proliferated densely.
b No melanin granules are observed in amelanotic melanoma.
c Tumor cells with a clear cytoplasm show intraepithelial spread
adjoining an invasive tumor. d Immunohistochemically, the tumor
cells are positive for HMB-45 (Human Melanoma Black-45)
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Preoperative chemoradiotherapy was performed for a Type
2 advanced cancer. In the resected specimen, only mild
stricture and wall thickening (arrow) are observed in the
lower esophagus.
Serial sectioning was performed for pathological exami-
nations. Histologically, fibrosis was observed in the stricture,
which can be regarded as the extent of the preexisting tumor.
Fig. 2-43 Resected specimen receiving chemoradiotherapy
Fig. 2-44 Grade 1: slightly effective. a 9100. b 9200 high-
magnification view of a
Fig. 2-45 Grade 2: moderately effective. a 9100. b 9200 High-
magnification view of a. a, b Small nests of a tumor are surrounded
by macrophages with foamy cytoplasm. Most of the residual cancer
cells show degeneration, and decreased staining with eosin. Tumor
nests are surrounded by inflammatory cells. The foamy cells are
regarded as a reaction to liquefactive necrosis. c Another section of
the same case. Scattered tumor cells show vacuolation of the
cytoplasm and nuclei, and are surrounded by marked fibrosis
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Tumor nests with abundant keratinization have unclear
borders, and are surrounded by inflammatory cell infiltra-
tion, foreign body giant cells, and granulation tissue with
marked fibrosis. Viable tumor cells are observed in the
center of the tumor. It is a characteristic finding that ker-
atinized material directly contacts the granulation tissue
without a basal layer or prickle cell layer. Numerous viable
tumor nests are observed also in other sections.
6. Barrett esophagus and adenocarcinoma in Barrett
esophagus
6.1.3. Barrett esophagus
6.1.3.1. Macroscopic findings (Fig. 2-47)
6.1.3.2. Pathological findings
Any of the following findings can be observed in Barrett
esophagus.
1. Esophageal glands or ducts beneath the overlying
columnar epithelium.
2. Squamous epithelial islands located in the columnar
epithelium
3. Double-layer muscularis mucosae beneath the overlying
columnar epithelium
Note: The presence of palisading vessels with a diameter
of more than 100 m in the lamina propria mucosae of the
lower esophagus suggests Barrett esophagus.
Types of Barrett mucosa
1. Specialized columnar epithelium (SCE)
Foveolar epithelium has goblet cell metaplasia (incomplete
intestinal metaplasia). Paneth cells are rarely observed.
2. Junctional type
Cardiac gland-like epithelium sometimes includes parietal
cells.
3. Gastric fundic type
The epithelium contains chief and parietal cells.
Note: If intestinal metaplasia is observed in Barrett
mucosa, it should be described
e.g.: Barrett mucosa with SCE (?) (Figs. 2-48, 2-49 and 2-50).
6.1.4. Adenocarcinoma in Barrett esophagus (Figs. 2-51,
2-52)
Fig. 2-46 Grade 3: Markedly effective. a Marked fibrosis is noted
beneath the squamous epithelium. b Masson staining reveals partial
disruption of muscular layer. Fibrosis is noted throughout the
esophageal wall. The extent of fibrosis can be regarded as the extent
of the preexisting tumor. c Disruption of the muscularis propria and
fibrosis are noted. d No viable cancer cell is observed, while foreign
body giant cells are scattered. The therapeutic effect is evaluated as
grade 3
Fig. 2-47 a Barrett esophagus and adenocarcinoma in Barrett
esophagus, 0-IIb. The squamocolumnar junction shows an irregular-
ity, with a tongue-like extension of the columnar-lined mucosa
towards the esophagus. b Iodine-stained specimen. Iodine staining
clearly shows a tongue-like extension of columnar-lined mucosa
measuring 30 mm (short segment Barrett esophagus: SSBE). Cancer-
ous lesion was detected pathologically in Barrett mucosa, but it is not
visible macroscopically. 0-IIb, pT1a-SMM
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Fig. 2-48 Barrett esophagus (specialized columnar epithelium): the
esophagus is covered by specialized columnar epithelium with
intestinal metaplasia. Squamous epithelium is visible on the distal
side (squamous island)
Fig. 2-49 Barrett esophagus (junctional type): a double-layered
muscularis mucosae (arrows) is present beneath the overlying
columnar epithelium. Esophageal glands are also observed in the
submucosal layer. Overlying columnar epithelium is of the cardiac
gland type
Fig. 2-50 Barrett esophagus (gastric fundic type): the mucosa
consists of fundic gland type columnar epithelium. Esophageal
glands are observed in the submucosal layer
Fig. 2-51 a Adenocarcinoma in Barrett esophagus. Grossly type 1. A
section of columnar epithelium measuring 85 mm in length and
continuously extending to the esophagus is regarded as long segment
Barrett esophagus. A protruding tumor (Type 1) is visible within the
section of Barrett esophagus. b Iodine-stained specimen shown in a.
Iodine staining clearly reveals the area of Barrett mucosa with
scattered iodine-stained squamous islands. The depth of tumor
invasion is pT1b
Fig. 2-52 Adenocarcinoma in Barrett esophagus. Barrett esophagus
with esophageal glands in the submucosal layer is covered with
well differentiated adenocarcinoma. The tumor has invaded beyond
the superficial muscularis mucosae, but has not reached the original
(deep) muscularis mucosae. Therefore, the depth of tumor invasion
should be assessed as pT1a-LPM
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Part III




The Japan Esophageal Society (JES) had adopted the
‘‘Response Evaluation Criteria in Chemotherapy for Solid
Tumors’’ published by the Japan Society of Clinical
Oncology (JSCO), which were based on the WHO evalu-
ation criteria, as criteria for response evaluations.
According to global changes from the WHO to the ‘‘Re-
sponse Evaluation Criteria in Solid Tumors (RECIST)’’
criteria, JSCO has already adopted these criteria, which has
led JES to the same decision. The response evaluation
criteria for the primary site of the esophageal cancer are
included in this revised version.
Concerning adapting RECIST into the present criteria,
the policy of RECIST is described to ensure its proper
use. Both the WHO and RECIST criteria are targeted to
evaluate the effect of antitumor agents on tumor shrink-
age. Their purposes are to estimate the response ‘as a
surrogate end point in clinical trials’. RECIST can be
used in daily clinical practice; however, it is not intended
for making any decisions on treatment strategy. Achiev-
ing a ‘‘partial response (PR)’’ with 50% reduction in
tumor size does not mean giving a definite advantage to
the patient. ‘‘Clinical improvement’’ may not correspond
to ‘‘objective tumor response’’ in daily practice. The
RECIST guidelines clearly state that ‘‘the defined criteria
are not necessarily developed further to be applicable or
complete in such a context’’. Physicians who are using the
present criteria should recognize that the RECIST criteria
are only for evaluating antitumor activity as a surrogate
end point in clinical trials.
The present criteria added the evaluation criteria for
primary tumor of the esophagus. These additional
descriptions are needed to define complete response (CR)
for the primary tumor, since the CR rate was more corre-
lated with prognosis after definitive chemoradiotherapy or
radiotherapy than response rate2). It should be noted that
these criteria are indicative not for pathological response
but for clinical response as a surrogate end point related to
prognosis. These criteria are defined for ‘‘evaluating tumor
reduction as an end point in clinical trials’’ and do not
attempt to determine the value of esophagography as an
evaluation tool in daily clinical practice. Although the
value of ‘‘PR’’ is not confirmed, this definition is described
in ‘‘Notes’’ since it may be used in cases of preoperative
therapy. The development of new imaging modalities, such
as positron-emission tomography (PET), may allow the
proposal of new criteria in the future.
1. Subjects
Subjects evaluated by the present criteria are patients with
esophageal cancer and treated with chemotherapy and/or
radiotherapy.
1.1. Classification of tumor lesions
1.1.1. Measurable lesions
Measurable lesions defined as lesions that can be accu-
rately measured in at least one dimension (greatest
dimension to be recorded) as C20 mm with conventional
techniques or as C10 mm with spiral CT scan.
1.1.2. Non-measurable lesions
All lesions other than those defined in 1.1.1.
1.1.3. Target lesions
Measurable lesions detected at baseline. A maximum of
five lesions per organ should be identified as ‘‘target
lesion’’.
1.1.4. Non-target lesions
Any other lesions (or sites of disease) should be identified
as ‘‘non-target lesions’’.
2. Methods for response evaluation
1. Because it is difficult to accurately measure the
primary site of the esophagus, it is defined as a
‘‘non-measurable lesion’’. Evaluation of reduction in
tumor size of the primary site should be done by
esophagoscopy (including biopsy, see 5.) in accor-
dance with the definition of ‘‘non-target lesion’’.
2. Either measurable or non-measurable lesions apart
from the primary esophageal lesion should be evalu-
ated according to the RECIST criteria.
3. Basically the same methods as used in baseline
evaluation should be adopted.
4. All measurements should be recorded in metric
notation.
3. Response evaluation criteria for target lesions
Evaluation of the target lesions should be done for up to 5
lesions greatest in dimension per organ and classified
according to the following criteria. Rates of decrease or
increase in the sum of the greatest dimensions are calcu-
lated by the following formula.
Rates of decrease of the greatest dimensions = {(sum of
the greatest dimensions at baseline - sum of the greatest
dimensions at evaluation)/sum of the greatest dimensions
at baseline)} 9 100%
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Increasing rate of the greatest dimensions = {(sum of
the greatest dimensions at evaluation - smallest sum of
the greatest dimensions since the treatment started)/small-
est sum of the greatest dimensions since the treatment
started} 9 100%
3.1. Complete response (CR)
The disappearance of all target lesions as well as secondary
changes associated with the tumors.
Note: In case of lymph node metastasis, CR is declared
if the size decreases to normal size or less.
3.2. Partial response (PR)
At least a 30% decrease in the sum of the greatest
dimensions of target lesions, taking as reference the base-
line sum of greatest dimensions.
3.3. Progressive disease (PD)
At least a 20% increase in the sum of greatest dimensions
of target lesions, taking as reference the smallest sum of
greatest dimensions recorded since the treatment started.
3.4. Stable disease (SD)
Neither PR nor PD.
4. Response evaluation criteria for non-target lesions
4.1. Complete response (CR)
The disappearance of all non-target lesions and normal-
ization of tumor marker level. In addition, the response of
the primary lesion must meet criterion 5.1: complete dis-
appearance of primary lesion on endoscopy.
4.2. Incomplete response/stable disease (IR/SD)
The persistence of one or more non-target lesion(s) and/or
the maintenance of tumor marker level above the normal
limits. In addition, the response of the primary lesion meets
criterion 5.2, incomplete response/stable disease of primary
lesion by endoscopy.
4.3. Progressive disease (PD)
The appearance of one or more new lesions and/or
unequivocal progression in existing non-target lesion(s). In
addition, the response of the primary lesion meets criterion
5.3, progressive disease of the primary lesion on endoscopy.
5. Response evaluation criteria for primary lesion using
endoscopy
5.1. Complete response of primary lesion (primary lesion
CR)
When conditions satisfy all of 1 to 4, the response is judged
as CR.
1. Disappearance of endoscopic findings suggesting the
presence of a tumor
The findings noted below should be judged as
possible tumor lesions and should not be judged as a
CR.
Eroding changes of the mucosa with an irregular
surface
Ulcerative lesions
Distinctly protruded changes (including protru-
sions suggestive of a submucosal tumor)
The findings noted below should not be judged as




Iodine-unstained areas or poorly stained areas
Biopsy-negative granulomatous small elevated
lesion
2. Negative endoscopic biopsy findings from the area of
the primary tumor
3. Entire esophagus can be observed using endoscopy.
4. No endoscopic findings of active esophagitis (e.g., flat
erosive findings, white coating) (Figs. 3-1, 3-2, 3-3,
3-4).
Fig. 3-1 Endoscopic findings of CR cases. a Before treatment: Type
3, cStage IV. b After treatment (5 months after CRT): scarring and
mild stenosis are visible. The endoscope could be passed through the
entire length of the esophagus. This case was judged as a CR
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5.2. Incomplete response/stable disease of primary lesion
(primary lesion IR/SD)
Response of the primary lesion is judged as IR/SD when its
response does not meet the conditions for complete
response (5.1) or progressive disease (5.3). PR is not
defined in the Japanese Classification since endoscopic
evaluation for partial response of the primary lesion is
difficult. If it is necessary to define PR in cases of preop-
erative chemotherapy or chemoradiotherapy, refer to the
criteria below (Figs. 3-5, 3-6, 3-7, 3-8).
1. Definition of PR in previous version of the guidelines
(9th edition)
Barium esophagography: marked shrinkage in tumor
shadow.
Endoscopy: shrinkage or flattening in the tumor or
its surrounding ridge, and shrinkage in ulcerative
lesion. Marked morphological improvement.
2. Adapt criteria of partial response defined in 3.2 for
primary lesions more than 20 mm in greatest dimen-
sion by helical CT scan.
[Reference]
Japanese Society for Esophageal Diseases. Guidelines for the Clinical and
Pathological Studies on Carcinoma of the Esophagus (in Japanese). 9th ed.
Kanehara Shuppan, Tokyo, 1999; 59–79.
Fig. 3-2 a Before treatment: Type 2, cStage III. b After treatment
(chemotherapy): The tumor has disappeared and only a scar remains.
This case was judged as a CR
Fig. 3-3 a Before treatment: Type 2, cStage III. b After treatment
(6 months after CRT): the tumor has disappeared, and only a scar
remains. c After treatment (6 months after CRT): the esophageal
mucosa has been stained brown. No unstained areas are present. An
endoscopic biopsy from the area of the primary tumor was negative
Fig. 3-4 Iodine staining after treatment. The esophageal mucosa was
stained unevenly by the iodine. Some areas stained poorly, while
others are dark brown. An endoscopic biopsy was negative, strongly
suggesting a CR
Fig. 3-5 Endoscopic findings of IR/SD cases. a Before treatment:
Type 2, cStage III. b, c After treatment (1 month after CRT): an ulcer
remains
Esophagus (2017) 14:37–65 63
123
5.3. Progressive disease of primary lesion (primary lesion
PD)
Distinct tumor growth or progression in esophageal
stenosis compared with the best condition during treatment
(Fig. 3-9).
6. Overall response
Overall responses for all possible combinations of tumor
responses in target and non-target lesions with or without











PR Non-PD No PR
SD Non-PD No SD
PD Any Yes or no PD
Any PD Yes or no PD
Any Any Yes PD
If there is no target lesion and only non-target lesions
are available (e.g. primary esophageal cancer without
lymph node metastasis), overall response is determined
only by the responses of the non-target lesions.
Fig. 3-7 Endoscopic findings of PR cases. a Before treatment: Type
1 ? 0-IIc cStage III. b After treatment (2 months after CRT): a
marked tumor reduction is visible, although an ulcer with a marginal
elevation is present
Fig. 3-8 a After treatment (3 months after CRT): a residual tumor
was strongly suggested by the presence of a submucosal tumor-like
protrusion. Cancer tissue is probably exposed on the top and distal
half of the tumor. b The exposed tumor was identified as a brownish
area with a central white coating using narrow band imaging
Fig. 3-6 a Before treatment: Type 2, cStage IVa. b After treatment
(CRT): the primary tumor has disappeared. A slightly depressed
change surrounded by a marginal elevation is still present. c Narrow
band imaging after treatment (CRT) shows a brownish area at the anal
margin. d Iodine staining after treatment (CRT): the brownish area
was identified as an unstained area. An endoscopic biopsy was
positive for malignant cells
Fig. 3-9 Endoscopic findings of a PD case. a Before treatment: Type
2, cStage III. b After treatment (2 months after CRT): the primary
tumor has mostly disappeared. c After treatment (5 months after
CRT): the relapsed tumor has increased in size
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7. Best overall response and confirmation
7.1. Complete response (CR)
Overall response of CR in serial assessments at an interval
of 4 weeks or more.
7.2. Partial response (PR)
Overall response of PR or better response (CR or PR) in
serial assessments at an interval of 4 weeks or more.
Endoscopic findings for IR/SD cases
7.3. Stable disease (SD)
When one of the following criteria is met.
1. Best overall response CR or PR was obtained, but
duration was less than 4 weeks.
2. Stable disease or better response in serial assessments at
an interval of 4 weeks or more, at 4 weeks or more after
the start of treatment. (If the first assessment is SD, and the
second assessment is of PD, it should be judged as PD.)
Note: If there is no target lesion (e.g. esophageal cancer
without metastasis), IR/SD is used as a description in
place of PD or SD.
7.4. Progressive disease (PD)
When none of above conditions is met.
Note: In phase II studies in which response rates are used
as end points, confirmation should be made with an
interval of 4 weeks or more. In phase III, studies in
which survival is used as the end point, the best overall
response without confirming response can be used.
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